Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Hematology · Graft-Versus-Host Disease

Prevention and Prophylaxis: Stopping GVHD Before It Starts

At a Glance

Graft-versus-host disease (GVHD) prevention, or prophylaxis, is a mandatory part of every allogeneic stem cell transplant. Patients receive targeted medications, such as tacrolimus, methotrexate, or post-transplant cyclophosphamide (PTCy), to stop aggressive donor T cells from attacking healthy tissues.

Because your body is receiving a brand-new immune system, your medical team’s first goal is to “train” that system to live peacefully with your healthy tissues. This is called prophylaxis (prevention). In the world of transplant medicine, prophylaxis is not optional; it is a standard and vital part of every allogeneic stem cell transplant [1][2].

Understanding the medications used to prevent GVHD also helps you and your team understand your risk profile, which is crucial if symptoms later develop and you need to move to active treatment.

The “Training” Medications

Prevention strategies have evolved rapidly over the last few years. While the medications are powerful, their job is highly specific: to quiet the donor T cells that might cause GVHD while allowing the other cells to grow and protect you from infection.

1. The Classic Foundation: Tacrolimus and Methotrexate

For many years, the standard “backbone” of prevention has been a combination of two drugs:

  • Tacrolimus (a calcineurin inhibitor): Usually started a few days before your transplant and continued for several months. It works by blocking the activation of T cells [1][3].
  • Methotrexate: Given in small doses on specific days immediately after your transplant to help suppress any early, aggressive T cell activity [2][3].

2. The Game-Changer: Post-Transplant Cyclophosphamide (PTCy)

One of the most significant advances in transplant history is the use of PTCy [1][4]. Instead of just suppressing the immune system, PTCy works by selectively removing the most aggressive donor T cells that would otherwise attack your body [5].

  • How it works: You receive high-dose cyclophosphamide (chemotherapy) on Day 3 and Day 4 after your transplant cells are infused [4].
  • Why it’s important: PTCy has made it possible for people to receive transplants from “half-matched” (haploidentical) donors, such as children or parents, with very low rates of severe GVHD [4][6]. It is now also becoming a standard for “fully matched” transplants because it significantly reduces the risk of chronic GVHD [1][7].

3. Precision Tools: ATG and Abatacept

Depending on your donor type and risk factors, your team may add other specialized medications:

  • ATG (Anti-Thymocyte Globulin): This is a protein that clears out T cells from your bloodstream. It is very common when the donor is not a sibling (unrelated donor) [1][8]. It is highly effective at reducing the risk of chronic GVHD [9][10].
  • Abatacept: A recently approved medication that acts like a “brake” on T cell activation. When added to standard medications, it has been shown to reduce the risk of severe acute GVHD, especially in patients with mismatched donors [11][12].

Comparing Strategies: Pros and Cons

No prevention plan is perfect; it is always a balance between stopping GVHD and allowing your new immune system to recover.

Strategy Major Pros Potential Cons
Tacrolimus / Methotrexate Decades of use; very predictable. Higher risk of chronic GVHD compared to newer methods [3].
PTCy (Post-Transplant Cyclo) Drastically reduces chronic GVHD; allows for “half-matched” donors [6]. Can slightly delay the recovery of your blood counts [13].
ATG Very effective at preventing both acute and chronic GVHD in unrelated transplants [9]. May increase the risk of certain viral infections (like CMV) during recovery [14].

Your specific plan is tailored to you. For example, if you have a matched sibling, your team might choose a different backbone than if your donor is an unrelated volunteer [1][15]. This customization is designed to give you the lowest possible risk of GVHD while keeping your new immune system strong enough to fight off infections.

Common questions in this guide

Why are prevention medications needed after a stem cell transplant?
Prevention medications, or prophylaxis, are required to help train your newly transplanted immune system to live peacefully with your body. They specifically suppress aggressive donor T cells to stop them from attacking your healthy tissues.
What is Post-Transplant Cyclophosphamide (PTCy)?
PTCy is a major advancement in GVHD prevention given as a chemotherapy infusion on the third and fourth days after your transplant. It works by removing the most aggressive donor T cells while allowing helpful cells to grow, drastically reducing the risk of severe chronic GVHD.
How do tacrolimus and methotrexate prevent GVHD?
Tacrolimus blocks the activation of T cells, while methotrexate is given in small doses right after a transplant to suppress early, aggressive T cell activity. Together, they have formed a traditional foundation for preventing GVHD for many years.
What are the side effects of GVHD prevention medications?
While vital for preventing GVHD, these medications lower your body's ability to fight off viral and bacterial infections during the recovery period. Depending on the specific drug, they may also cause other side effects like mouth sores, delayed blood count recovery, or changes in kidney function.
Will my GVHD prevention plan be different if my donor is a family member?
Yes, your specific prevention plan is highly tailored to your donor type. Patients with a fully matched sibling usually receive a different medication combination than those with an unrelated volunteer or a half-matched (haploidentical) donor.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific 'prevention backbone' you have planned for me, and why is it the best fit for my donor type?
  2. 2.If we are using post-transplant cyclophosphamide (PTCy), how will that change my medication schedule in the days immediately following the transplant?
  3. 3.Will I also be receiving abatacept or ATG, and what are the specific reasons for adding these to my plan?
  4. 4.How will these prevention medications affect my risk of infections during the first few months after transplant?
  5. 5.What signs of toxicity from these medications should I be watching for (e.g., changes in kidney function or mouth sores)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.

    Penack O, Marchetti M, Aljurf M, et al.

    The Lancet. Haematology 2024; (11(2)):e147-e159 doi:10.1016/S2352-3026(23)00342-3.

    PMID: 38184001
  2. 2

    Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study.

    Shiratori S, Suto K, Hasegawa Y, et al.

    Transplantation and cellular therapy 2026; (32(3)):339.e1-339.e9 doi:10.1016/j.jtct.2025.10.035.

    PMID: 41205871
  3. 3

    A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.

    Törlén J, Ringdén O, Garming-Legert K, et al.

    Haematologica 2016; (101(11)):1417-1425 doi:10.3324/haematol.2016.149294.

    PMID: 27662016
  4. 4

    The development of post-transplant cyclophosphamide: Half a century of translational team science.

    O'Donnell PV, Jones RJ

    Blood reviews 2023; (62()):101034 doi:10.1016/j.blre.2022.101034.

    PMID: 36435690
  5. 5

    Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.

    Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L

    Seminars in hematology 2016; (53(2)):90-7.

    PMID: 27000732
  6. 6

    Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis: current status and optimization strategies.

    Fuji S, Ohmoto A

    Current opinion in immunology 2025; (97()):102662 doi:10.1016/j.coi.2025.102662.

    PMID: 40974838
  7. 7

    Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease.

    Abedin S, Hamadani M

    Current hematologic malignancy reports 2024; (19(6)):246-255 doi:10.1007/s11899-024-00741-y.

    PMID: 39520614
  8. 8

    Clinical study of graft-versus-host disease prophylaxis in unrelated hematopoietic stem cell transplantation for pediatric nonmalignant diseases with different doses anti-human T-lymphocyte immunoglobulin.

    Atay D, Akcay A, Yenigurbuz FD, et al.

    Pediatric transplantation 2021; (25(8)):e14098 doi:10.1111/petr.14098.

    PMID: 34313359
  9. 9

    Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis.

    Yang X, Li D, Xie Y

    Frontiers in oncology 2021; (11()):717678 doi:10.3389/fonc.2021.717678.

    PMID: 34490116
  10. 10

    Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes.

    Song ZY, Ren HY, Dong YJ, et al.

    Cancer management and research 2020; (12()):12287-12300 doi:10.2147/CMAR.S283855.

    PMID: 33311999
  11. 11

    Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.

    Khandelwal P, Yeh RF, Yu L, et al.

    Transplantation 2021; (105(4)):891-896 doi:10.1097/TP.0000000000003327.

    PMID: 32467478
  12. 12

    Role of abatacept in the prevention of graft-versus-host disease: current perspectives.

    Ngwube A, Rangarajan H, Shah N

    Therapeutic advances in hematology 2023; (14()):20406207231152644 doi:10.1177/20406207231152644.

    PMID: 36845849
  13. 13

    Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study.

    Kerbauy MN, Rocha FA, Arcuri LJ, et al.

    Haematologica 2025; (110(3)):640-650 doi:10.3324/haematol.2024.285921.

    PMID: 39279428
  14. 14

    Optimizing anti-thymocyte globulin dosing in allogeneic hematopoietic stem cell transplantation: individualized approaches and clinical implications.

    Wang H, Yang H, Du J, et al.

    Frontiers in immunology 2025; (16()):1634157 doi:10.3389/fimmu.2025.1634157.

    PMID: 40861446
  15. 15

    Posttransplant cyclophosphamide beyond haploidentical transplantation.

    Arcuri LJ, Ribeiro AAF, Hamerschlak N, Kerbauy MN

    Annals of hematology 2024; (103(5)):1483-1491 doi:10.1007/s00277-023-05300-8.

    PMID: 37261557

This page provides educational information about GVHD prevention strategies and medications. It does not replace professional medical advice from your transplant team or hematologist.

Get notified when new evidence is published on Graft versus host disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.